2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
30
HR+/HER2- Advanced Breast Cancer
3
Breast Cancer Metastatic
3
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Advanced Breast Cancer
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
HR Positive HER2 Negative Advanced Breast Cancer
1
HER2-positive Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasm Female
1
Breast Diseases
1
Brain Neoplasms
1
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
1
Interventions
pembrolizumab
161
Carboplatin
145
Paclitaxel
125
Cyclophosphamide
94
130-nm albumin-bound paclitaxel
66
Capecitabine
64
Gemcitabine
54
Doxorubicin
50
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
41
Cisplatin
38
sacituzumab govitecan
34
Nivolumab
34
olaparib
32
Epirubicin
32
Specimen Handling
28
Docetaxel
28
eribulin
27
Bevacizumab
26
durvalumab
25
Drug Therapy
25
Biopsy
24
camrelizumab
23
Magnetic Resonance Spectroscopy
22
toripalimab
19
Radiotherapy
17
spartalizumab
16
Everolimus
15
veliparib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
dalpiciclib
×
Clear all
NCT05582499
2025-08-22
FASCINATE-N
Fudan University
Phase 2
Recruiting
716 enrolled